Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Wilson

Showing results (1-10 of 125) with videos related to

Pageof 13
Sort By:
Science and Engineering Ethics|December 16, 2011
Using the Chernobyl incident to teach engineering ethicsWilliam R Wilson
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|August 28, 2009
Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: Application to a pharmacokinetic studyYongchuan Gu, William R Wilson
Nature Reviews. Cancer|May 25, 2011
Targeting hypoxia in cancer therapyWilliam R Wilson, Michael P Hay
Expert Review of Anticancer Therapy|October 18, 2002
Potential of DMXAA combination therapy for solid tumorsBruce C Baguley, William R Wilson
Nature Reviews. Cancer|June 2, 2004
Exploiting tumour hypoxia in cancer treatmentJ Martin Brown, William R Wilson
The Biochemical Journal|March 14, 2013
FSL-61 is a 6-nitroquinolone fluorogenic probe for one-electron reductases in hypoxic cellsJiechuang Su, Christopher P Guise, William R Wilson
Nature Reviews. Clinical Oncology|July 30, 2021
Therapeutic targeting of the hypoxic tumour microenvironmentDean C Singleton, Andrew Macann, William R Wilson
International Journal of Pharmaceutics|November 23, 2016
pH-Sensitive PEGylated liposomes for delivery of an acidic dinitrobenzamide mustard prodrug: Pathways of internalization, cellular trafficking and cytotoxicity to cancer cellsMimi M Yang, William R Wilson, Zimei Wu
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 19, 2009
Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs, and humansYongchuan Gu, Graham J Atwell, William R Wilson
The Journal of Pharmacology and Experimental Therapeutics|March 24, 2011
Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapyYongchuan Gu, Malcolm D Tingle, William R Wilson
Pageof 13

Showing results (1-10 of 125) with videos related to

Sort By:
Pageof 13
Science and Engineering Ethics|December 16, 2011
Using the Chernobyl incident to teach engineering ethicsWilliam R Wilson
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|August 28, 2009
Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: Application to a pharmacokinetic studyYongchuan Gu, William R Wilson
Nature Reviews. Cancer|May 25, 2011
Targeting hypoxia in cancer therapyWilliam R Wilson, Michael P Hay
Expert Review of Anticancer Therapy|October 18, 2002
Potential of DMXAA combination therapy for solid tumorsBruce C Baguley, William R Wilson
Nature Reviews. Cancer|June 2, 2004
Exploiting tumour hypoxia in cancer treatmentJ Martin Brown, William R Wilson
The Biochemical Journal|March 14, 2013
FSL-61 is a 6-nitroquinolone fluorogenic probe for one-electron reductases in hypoxic cellsJiechuang Su, Christopher P Guise, William R Wilson
Nature Reviews. Clinical Oncology|July 30, 2021
Therapeutic targeting of the hypoxic tumour microenvironmentDean C Singleton, Andrew Macann, William R Wilson
International Journal of Pharmaceutics|November 23, 2016
pH-Sensitive PEGylated liposomes for delivery of an acidic dinitrobenzamide mustard prodrug: Pathways of internalization, cellular trafficking and cytotoxicity to cancer cellsMimi M Yang, William R Wilson, Zimei Wu
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 19, 2009
Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs, and humansYongchuan Gu, Graham J Atwell, William R Wilson
The Journal of Pharmacology and Experimental Therapeutics|March 24, 2011
Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapyYongchuan Gu, Malcolm D Tingle, William R Wilson
Pageof 13